Compare NNOX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNOX | SWKH |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.8M | 205.9M |
| IPO Year | 2020 | 1999 |
| Metric | NNOX | SWKH |
|---|---|---|
| Price | $3.11 | $17.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.1M | 8.9K |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | $12,302,000.00 | ★ $40,149,000.00 |
| Revenue This Year | $20.19 | $52.93 |
| Revenue Next Year | $137.69 | N/A |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | 15.19 | ★ 62.38 |
| 52 Week Low | $2.76 | $13.17 |
| 52 Week High | $9.20 | $20.49 |
| Indicator | NNOX | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 56.34 |
| Support Level | $2.90 | $17.10 |
| Resistance Level | $3.20 | $17.63 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 82.72 | 70.49 |
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.